Author of

• 31865

  +

  P2.18 - Treatment of Locoregional Disease - NSCLC (ID 191)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Treatment of Locoregional Disease - NSCLC
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31877

    +

    P2.18-09 - Age Does Not Affect the Benefit of Modern Chemoradiation for LA-NSCLC Patients (Now Available) (ID 1884)

    10:15 - 18:15  |  Author(s): Elisabetta Molfese
    • Abstract
    • Slides

    Background
    

    The standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC) is concurrent chemoradiation which achieves the better results but is affected by higher toxicities. Even if literature data document a significant advantage also for elderly population, these selected group of patients is usually underrepresented in randomized trials. This study analyzed treatment and outcomes at our institution according to elderly (>70 years old) or younger (≤ 70 years) age.

    Method
    

    A secondary analysis on patients with stage III NSCLC treated between January 1992 and September 2014 with concurrent chemoradiation with radical intent enrolled in previous published trials in our institution were analyzed. Factors analyzed included Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex, stage, histology, treatment period and esophageal and lung toxicities.

    Result
    

    A secondary analysis on 347 patients (≤70years: 188; >70years: 159) with stage III NSCLC treated with concurrent chemoradiation enrolled in previous published trials in our institution were analyzed (age range, 39-92 years). Elderly patients were more frequently male (85% and 72%; p=0.003) and stage IIIB (49% and 34%, p=0.008). ECOG was 0-1 in all cases (elderly: 36% and 29%, p=0.451). No differences were reported according to tumor histology.

    Median survival was similar between the younger and elderly patients (20,8 and 19,2 months respectively; p=0.503 ).

    A significant difference in overall survival was appreciated according to treatment period also for elderly population. Overall survival of all patients treated between 1992-2005 and 2006-1014 was 17.8 and 25,9 months, respectively (p<0.001). According to the same periods, elderly group survival was 16,5 and 24,9 months (p=0.002).

    No significant differences were reported in esophageal and lung toxicities between elderly and younger patients (Esophageal G2: 18.6% and 21%; Esophageal G3: 1,7% and 2,6%; Lung G2: 6,4% and 6,3%; Lung ≥G3: 5,7% and 3,1%, respectively).

    Conclusion
    

    In this series elderly patients in clinical good condition with locally advanced NSCLC treated with concurrent chemoradiotherapy reached interesting results in terms of overall survival without increased toxicity. The improved outcome obtained in younger patients in the modern era is achievable also for this selected elderly population.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.